MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$20,173,129
EPS
-$11.77
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development expenses
959,742
901,144
-274,634.5*
619,693
General and administrative expenses
5,319,018
11,284,550
5,424,982*
1,224,546
Total operating expenses
6,278,760
12,185,694
5,150,347.5
1,844,239
Loss from operations
-6,278,760
-12,185,694
-5,150,347.5*
-1,844,239
Unrealized gain from changes in fair value of digital assets
-13,178,928
-22,078,601
453,087*
-
Realized gain on sale of digital assets
1,704,378
15,100
5,597,696.5*
-
Trading gains, net
282,989
2,029
24.25*
-
Digital assets received as yield income
282,732
-
-
-
Foreign currency gains/(losses), net
458
-1,567
-130.25*
-
Change in fv of warrant liability
-
-
11,188.5*
-12,859
Change in fair value of derivative
-215,993
-48,279
-13,786.5*
-
Interest income
21,764
7
85.5*
56,426
Interest expense
3,223,755
859,405
238,978.5*
6,301
Total other income (expense)
-13,894,369
-22,874,158
5,814,382.5*
62,984
Net gain
-20,173,129
-35,059,852
664,035
-1,781,255
Basic EPS
-11.77
-2.26
0.068
-0.14
Diluted EPS
-11.77
-2.26
0.068
-0.14
Basic Average Shares
1,713,402
15,513,389
9,700,611
12,575,983
Diluted Average Shares
1,713,402
15,513,389
9,700,611
12,575,983
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain
-$20,173,129
(-657.76%↓ Y/Y)
Total other income
(expense)
-$13,894,369
(-812161.31%↓ Y/Y)
Loss from operations
-$6,278,760
(-135.70%↓ Y/Y)
Realized gain on sale of
digital assets
$1,704,378
Trading gains, net
$282,989
Digital assets received
as yield income
$282,732
Change in fair value of
derivative
-$215,993
Interest income
$21,764
(42.74%↑ Y/Y)
Foreign currency
gains/(losses), net
$458
Unrealized gain from
changes in fair value of...
-$13,178,928
Interest expense
$3,223,755
(13883.50%↑ Y/Y)
Total operating
expenses
$6,278,760
(135.70%↑ Y/Y)
General and
administrative expenses
$5,319,018
(164.35%↑ Y/Y)
Research and development
expenses
$959,742
(47.25%↑ Y/Y)
Buy us a coffee
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)